Samantha Budd Haeberlein

TL;DR: This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.

TL;DR: The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provided a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with treatment in patients with mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease dementia as discussed by the authors.

TL;DR: This review will summarize the “A, T, N System” (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development.

TL;DR: Repeated administration of the anti-tau monoclonal antibody BIIB092, at doses of up to 2100 mg, appears to be well tolerated in participants with progressive supranuclear palsy.

TL;DR: EMERGE and ENGAGE are two 18‐month, randomized, double‐blind, placebo‐controlled, global Phase 3 studies with identical design that evaluated the efficacy and safety of aducanumab in patients aged 50–85 years with early Alzheimer’s disease.